2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Aurinia Pharmaceuticals said it has settled patent infringement litigation with Teva Pharmaceuticals over Teva's application to sell a generic 7.9 mg voclosporin capsule in the United States. Under the settlement, Teva has stipulated that Aurinia's two U.S. patents are enforceable, valid and would be infringed, and Teva may launch no earlier than December 7, 2036, subject to earlier contingencies and FDA approval. The filing gives no financial figures, and Aurinia's other patent actions continue.
Teva stipulated that U.S. Patent Nos. 10,286,036 and 11,622,991 are enforceable, valid and would be infringed, and that the patents expire in December 2037.
Teva may launch its generic voclosporin no earlier than December 7, 2036, unless defined contingencies occur earlier.
Teva's U.S. launch also depends on FDA approval of its generic product.
Aurinia's patent infringement actions against five other companies continue in the U.S. District Court for the District of New Jersey.
The Metals Company said the National Oceanic and Atmospheric Administration published its consolidated application for an exploration license and commercial recovery permit for the TMC USA-A area in the Federal Register. The publication starts a public comment period that NOAA views as a prerequisite to certification, and NOAA still has to certify the application, complete an environmental review, and make a final licensing decision.
NOAA published the TMC USA-A consolidated application in the Federal Register; NOAA had determined the application fully compliant on April 28, 2026.
The application covers a proposed exploration and commercial recovery area of about 65,000 square kilometers, up from about 25,000 square kilometers in the April 2025 applications, with an estimated 619 million tonnes of wet nodules and pot
Remaining steps include certification, an environmental review with a draft Environmental Impact Statement for public comment, and a final determination on the license and permit.
The filing does not state a financial result, guidance change or timeline for a final NOAA decision.
Mereo BioPharma Group plc was told by Nasdaq that it has not yet regained the $1.00 minimum bid price required for continued listing, but it qualifies for an additional 180-day period, running to February 16, 2027. The notice has no immediate effect on the listing of its American Depositary Shares, though a failure to regain compliance by then would lead to a delisting notice that the company could appeal.
Nasdaq's first notice, dated February 17, 2026, set an initial compliance deadline of August 17, 2026.
On August 18, 2026, Nasdaq issued a second notice granting an additional 180 calendar days, until February 16, 2027.
Regaining compliance requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
The company says the listing is unaffected for now and that it may consider options to regain compliance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.